Nosál R, Jancinová V, Ondrias K, Jakubovský J, Balgavý P
Biochim Biophys Acta. 1985 Dec 5;821(2):217-28. doi: 10.1016/0005-2736(85)90090-2.
beta-Adrenoceptor blocking drugs interfere with adenosine diphosphate-stimulated platelet aggregation. Alprenolol, exaprolol, Kö 1124 and propranolol inhibited the aggregation, metipranolol decreased the extent and rate of aggregation significantly. Atenolol potentiated the aggregation measured by amplitude significantly. The interaction of beta-adrenoceptor blocking drugs with aggregation correlated with the displacement of calcium ions from binding sites in isolated platelets and the fluidization of the whole platelets and isolated platelet membrane as measured with electron spin resonance of the spin probe. The most potent were highly liposoluble drugs alprenolol, exaprolol, metipranolol and propranolol which increased the calcium displacement and membrane fluidity, the least active was atenolol decreasing these phenomena. The inhibition by beta-adrenoceptor blocking drugs of stimulated platelet aggregation is rather a result of unspecific than specific receptor interaction.
β-肾上腺素受体阻断药干扰二磷酸腺苷刺激的血小板聚集。阿普洛尔、依沙洛尔、Kö 1124和普萘洛尔抑制聚集,美替洛尔显著降低聚集程度和速率。阿替洛尔显著增强了通过幅度测量的聚集。β-肾上腺素受体阻断药与聚集的相互作用与钙离子从分离血小板结合位点的位移以及用自旋探针的电子自旋共振测量的全血小板和分离血小板膜的流动性相关。最有效的是高度脂溶性药物阿普洛尔、依沙洛尔、美替洛尔和普萘洛尔,它们增加了钙位移和膜流动性,活性最低的是阿替洛尔,可降低这些现象。β-肾上腺素受体阻断药对刺激的血小板聚集的抑制作用与其说是特异性受体相互作用的结果,不如说是非特异性的。